Introduction {#Sec1}
============

Up to 80% of children will experience at least one potentially traumatic experience during childhood, and posttraumatic stress disorder (PTSD) is common among children and adolescents with a history of trauma \[[@CR1]\]. PTSD-related nightmares and sleep disturbances in pediatric patients with PTSD may independently affect the severity and course of PTSD in youth \[[@CR2]\]. Currently, trauma-focused psychotherapies represent the first line treatments for children with PTSD, with Trauma Focused Cognitive Behavioral Therapy (TF-CBT) the most studied of the trauma-based interventions \[[@CR3]\]; however, treatment response varies \[[@CR4], [@CR5]\], and some intrusive symptoms may fail to improve with these trauma-focused psychotherapies. Moreover, there is little guidance for clinicians regarding the appropriate use of adjunctive pharmacotherapy in this population. To date, no placebo-controlled trials of selective serotonin reuptake inhibitors (SSRIs) in youth with PTSD have demonstrated their superiority to placebo \[[@CR6], [@CR7]\], and studies of antiadrenergics---which are commonly utilized in adults with PTSD---are limited to case reports \[[@CR8]--[@CR10]\] and open label trials \[[@CR11]\].

The autonomic nervous system (ANS), a principal effector of stress response, has been implicated in the pathophysiology of PTSD \[[@CR12]\] and may potentiate altered sleep architecture after trauma (e.g. including increased stage 1 sleep, decreased slow-wave sleep and increased activity in REM sleep) \[[@CR13], [@CR14]\]. Central norepinephrine concentrations are both elevated in adults with chronic PTSD and correlated with the severity of PTSD symptoms \[[@CR15]\]. Changes in ANS function may also predict trauma-related psychopathology in children. Pediatric maltreatment victims have been found to have increased 24-h urinary catecholamine excretion \[[@CR16], [@CR17]\], and elevated plasma norepinephrine levels are present in children who subsequently develop PTSD within 6 months of a motor vehicle accident (MVA) compared to MVA victims who do not develop PTSD \[[@CR18]\] over the same period. Additionally, salivary α-amylase (sAA) concentrations, a marker of ANS activity, have been associated with PTSD symptoms in recently sexually abused girls and correlate with the severity of intrusive symptoms \[[@CR19]\], including nightmares.

Antiadrenergic Agents {#Sec2}
---------------------

Given that research has consistently demonstrated increased noradrenergic tone in both adults \[[@CR12]\] and youth with PTSD \[[@CR19]\], several investigators have explored the efficacy of antiadrenergic agents for the prevention and treatment of pediatric PTSD. Propranolol is a centrally active antagonist of norepinephrine at the postsynaptic beta adrenoreceptor. It has been used off-label for the treatment of situational anxiety, and Famularo and colleagues demonstrated reductions in PTSD symptoms in an open label pilot study \[[@CR20]\]. However, subsequent studies examining the use of propranolol among trauma-exposed youth have had negative results. In youth aged 10--18 years with MVA-related trauma, a randomized controlled trial (RCT) failed to detect differences between propranolol-treated youth and those who received placebo in terms of PTSD symptom severity or incidence of PTSD diagnosis at 6 weeks \[[@CR21]\].

Alpha-2 (α~2~) agonists (e.g. clonidine and guanfacine) are commonly utilized in the treatment of youth with attention-deficit/hyperactivity disorder (ADHD) \[[@CR22]\] and are also utilized for pediatric patients with impulsive aggression and insomnia. These agents, agonists at the inhibitory pre-synaptic α~2~-adrenoreceptors, are prescribed to trauma-exposed children with severe trauma-related behavioral manifestations, including sleep disturbances \[[@CR23]\]. Clonidine has been shown in open label trials to have the potential to attenuate hyperarousal, and in abused youth, clonidine decreases reenactment symptoms \[[@CR24], [@CR25]\]. Similarly, case reports of guanfacine use suggest improvement in nightmares in children with PTSD \[[@CR26]\]. However, when guanfacine was examined in an open label trial of PTSD, although improvements were noted for reexperiencing and hyperarousal symptoms \[[@CR11]\], most children with nightmares did not experience resolution of their nightmares while taking extended-release guanfacine \[[@CR27]\].

In adults with PTSD, the efficacy of the α~1~-antagonist prazosin for the treatment of nightmares and dysomnia associated with PTSD is supported by multiple double-blind, placebo-controlled studies in both military and non-military populations \[[@CR28]--[@CR33]\]. Prazosin is the only α~1~-blocking agent at the postsynaptic α~1~-adrenoreceptor that blocks the effect of norepinephrine centrally when administered peripherally \[[@CR34]\]. However, prazosin has not been systematically evaluated in the pediatric population, and a review of the pediatric literature identified fewer than five cases describing the potential efficacy and tolerability of prazosin in children and adolescents \[[@CR8], [@CR9]\]. Thus, due to a lack of data, it is unclear whether prazosin is tolerated and associated with improvement in nightmares and sleep problems in children and adolescents with PTSD. With this in mind, we retrospectively evaluated the tolerability and clinical course of adjunctive prazosin in pediatric patients with PTSD who experienced significant PTSD-associated nightmares and sleep disturbances.

Methods {#Sec3}
=======

Participants {#Sec4}
------------

This retrospective evaluation of prazosin in traumatized youth was approved by the University of Utah and Intermountain Healthcare Institutional Review Boards. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. All children were treated at a single academic hospital-based mental health center that specialized in pediatric trauma and were already receiving evidence-based psychotherapy at the time of referral for psychiatric consultation. As is the practice in the clinic, regardless of the modality \[TF-CBT, dialectical behavior therapy (DBT), parent child interaction therapy (PCIT), eye movement desensitization and reprocessing (EMDR)\], all families of children identified as having persistent nightmares were provided coping skills and sleep hygiene guidance as part of their psychotherapy to address their nightmares. Children were only referred for medication evaluation if there were no improvements in nightmares and sleep-related problems during psychotherapy. Of 40 children who were psychiatrically evaluated and in whom prazosin was prescribed, six were lost to follow-up and 34 had at least one follow-up visit after starting the medication.

Prazosin-treated patients were between the ages of 5--18 \[mean age ± standard deviation (SD) 13.4 ± 2.9\] years and had experienced various forms of trauma, including sexual abuse (76%), family violence (38%) and bullying (18%). Although all patients met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for PTSD at the time of evaluation, comorbidity was common, with 65% with a comorbid diagnosis, most commonly anxiety (50%) and depressive disorders (32%). Nearly one-half (41%) of the children were treated with an SSRI and 6% were treated with a stimulant at some point during their use of prazosin.

Consensus guidelines suggest dose titration of prazosin at 1 mg/week until sufficient improvement in sleep and/or reduction in nightmares is observed \[[@CR35]\]. Prior to the initiation of prazosin treatment, families were routinely asked about the child's past medical history and the current state of symptoms and the family history were reviewed, with special attention paid to cardiovascular symptoms and risk. In the present sample, prazosin was initiated at 1 mg at bedtime (QHS) in all patients to decease the risk of first dose orthostatic hypotension-related syncope \[[@CR36]\]. However, we found that patients tolerated titration from 1 to 2 mg QHS following three consecutive doses of 1 mg QHS. If nightmares failed to respond to prazosin at 2 mg after three additional nights, prazosin was generally titrated to 3 mg QHS. Most patients had their first follow-up visit 2 weeks after the initiation of prazosin, and for those who would eventually need a higher dose, they returned to clinic having taken 3 mg at night for 1 week, providing sufficient data were available to determine an appropriate increase in dose if necessary. The final prazosin dosage ranged from 1 to 15 mg in a single dose \[administered QHS, 0.02--0.3 mg/kg body weight (BW)\], with 35% of patients receiving ≥5 mg/kg BW and 24% of patients receiving ≥0.1 mg/kg BW. Prazosin was generally discontinued around the time that the evidence-based trauma therapy was terminated.

Clinical Measurements {#Sec5}
---------------------

As part of standard clinical practice, all patients were administered the UCLA PTSD reaction index (UCLA PTSD RI) for DSM-5 \[[@CR37]\] prior to starting prazosin and at each follow-up visit. Additionally, most adolescents completed the Adolescent Dissociative Experiences Scale (ADES) \[[@CR38]\] at the time of the initial visit to characterize dissociative symptoms. As part of routine clinical care, vital signs were obtained at the initial and each subsequent visit, and the Clinical Global Impressions of Improvement (CGI-I) scale \[[@CR39]\] was documented at each visit to indicate clinical response from baseline.

The UCLA PTSD RI version for DSM-5 is a 31-item measure that captures the presence and frequency of intrusive, avoidant, negative cognition/mood, hyperarousal and dissociative symptoms in PTSD. The DSM-IV version has been validated in several studies \[[@CR40], [@CR41]\], and the DSM-5 version is currently undergoing validation. For our clinical purposes, we developed a unique sleep subscale of the UCLA PTSD RI to monitor sleep problems (questions 10 and 21 from the UCLA PTSD RI) with a possible score range of 0 to 8.

The ADES is a 30-item self-report measure that assesses dissociative symptoms. For each question, symptom frequency is rated on a scale of 0 to 10, with 10 signifying that the symptom occurs "all the time." Prior studies have demonstrated that scores of ≥3.7 suggest clinically significant dissociation \[[@CR38]\].

For youth with comorbid depression, the diagnosis was made based on results of the Quick Inventory of Depression Symptomatology (QIDS) \[[@CR42]\] and clinical interview. For comorbid anxiety disorders, the diagnosis was made based on the Screen for Child Anxiety Related Disorders (SCARED) \[[@CR43]\] and clinical interview.

Analytic Strategy {#Sec6}
-----------------

Continuous variables were summarized by the mean ± SD, median with interquartile range and range; categorical variables were summarized as count with the percentage. Linear mixed effects models were used to compare each outcome variable with time (months) as the fixed effect, including a random effect for each subject to account for correlation among repeat measures within subjects. The coefficient of time and its 95% confidence interval and *p* value were reported for each model. Statistical analyses were conducted in R (version 3.3.1; R Foundation for Statistical Computing, Vienna, Austria) using two-tailed tests, and findings were considered to be statistically significant at *p* ≤ 0.05 level.

Results {#Sec7}
=======

Demographic and Clinical Characteristics of the Patients {#Sec8}
--------------------------------------------------------

Most patients were female, and most patients were treated with TF-CBT (79%). Symptom severity was high at the beginning of treatment, and 35% of patients (*n* = 12) reported clinically significant dissociation. Additional demographic and clinical variables are shown in Table [1](#Tab1){ref-type="table"}.Table 1The pediatric patients with posttraumatic stress disorder (*N* = 34) reviewed in this study who were treated with prazosin and attended at least one follow-up visitPatient demographic and clinical variablesValuesAge at intake (years)  Mean (SD)13.38 (2.89)  Range5--18Female gender, *n* (%)28 (82.35)Race/ethnicity, *n* (%)  African American3 (8.82)  Caucasian22 (64.71)  Latino/a7 (20.59)  Native American2 (5.88)Primary trauma *n* (%)  Sexual abuse,26 (76.47)  Family violence13 (38.24)  Bullying6 (17.65)  Vicarious traumatic death5 (14.71)Dissociation mean score (SD)3.96 (1.97)Comorbid diagnosis, *n* (%)22 (64.71)  Depressive disorder11 (32.35)  Anxiety disorder17 (50)  Attention-deficit/hyperactivity disorder (ADHD)3 (8.82)Primary psychotherapy type, *n* (%)  Dialectical behavior therapy (DBT)6 (17.65)  Eye movement desensitization and reprocessing (EMDR)1 (2.94)  Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)27 (79.41)Psychotropic medication, *n* (%)  Selective serotonic reuptake inhibitor (SSRI)14 (41.18)  Stimulant2 (5.88)Side effects reported during treatment  Side effects, *n* (%)8 (23.53)    Dizziness6 (17.65)    Anxiety3 (8.82)    Headache2 (5.88)Follow-up time (months)  Mean (SD)2.34 (1.87)  Median (IQR)1.70 (1.00, 2.80)Number of visits, *n* (%)  214 (41.18)  311 (32.35)  4+9 (26.47)SD, Standard deviation; IQR interquartile range

Symptom Changes During Treatment {#Sec9}
--------------------------------

Prazosin treatment was associated with significant improvement in PTSD symptoms, as assessed with the UCLA RI (baseline 51.7 ± 10.4; endpoint 35.1 ± 14.5; *p* \< 0.0001). The sleep subscale (combination of questions 10 and 21 from the UCLA PTSD RI) showed significant improvement (baseline 7.32 ± 0.94; endpoint 3.09 ± 2.40; *p* \< 0.0001). Similar improvements were noted for PTSD symptom clusters, including intrusive (baseline 13.7 ± 3.5; endpoint 8.5 ± 4.4; *p* \< 0.0001), avoidance (baseline 6.0 ± 2.0; endpoint 4.5 ± 2.0; *p* = 0.002), negative or decreased cognition and mood (baseline 16.7 ± 4.6; endpoint 12.8 ± 5.3; *p* \< 0.0001) and arousal symptoms (baseline 15.3 ± 3.3; endpoint 9.8 ± 4.7; *p* \< 0.0001) symptoms (Table [2](#Tab2){ref-type="table"}). Of the 34 patients enrolled in the study, 35% (*n* = 12) were treated with ≥5 mg (range 5--15 mg administered orally QHS) and 24% were treated with \>0.1 (0.1--0.3)  mg/kg BW (Fig. [1](#Fig1){ref-type="fig"}). No statistically significant differences were noted between patients treated with a low dose (\<5 mg/night or \<0.1 mg/kg BW/night) and high dose (≥5 mg/night or ≥0.1 mg/kg BW/night) prazosin in terms of baseline symptom severity, age or sex.Table 2Posttraumatic stress disorder symptoms and vital signs at baseline and last time point, and change-over timeVariableBaseline, mean (SD)Last time point, mean (SD)Time estimate (95% CI)SignificanceSleep score (range 0--8)7.32 (0.94)3.09 (2.40)−0.939 (−1.219, −0.659)\<0.0001\*UCLA score51.65 (10.42)35.06 (14.52)−4.5 (−5.821, −3.179)\<0.0001\*Intrusive13.65 (3.52)8.53 (4.41)−1.241 (−1.691, −0.791)\<0.0001\*Avoidance6.03 (1.95)4.53 (1.95)−0.35 (−0.565, −0.134)0.0019\*Negative mood16.71 (4.61)12.75 (5.27)−1.217 (−1.682, −0.751)\<0.0001\*Arousal15.26 (3.33)9.78 (4.72)−1.62 (−2.062, −1.178)\<0.0001\*Weight54.51 (17.16)55.80 (17.32)0.331 (0.15, 0.512)0.0005\*Systolic blood pressure104.64 (8.88)106.83 (11.81)0.103 (−0.901, 1.106)0.84Diastolic blood pressure61.30 (8.15)62.63 (8.30)0.565 (−0.269, 1.4)0.18Heart rate77.58 (13.03)81.83 (10.70)1.212 (−0.117, 2.541)0.07\* Significant difference between baseline and last time point at *p* ≤ 0.05CI, Confidence interval Fig. 1Plots of sleep scores in prazosin-treated patients. Each *line* represents the reported sleep symptom score (range 0--8) for individual patients. *Decreases* represent symptomatic improvement. **a** Rate of improvement based on final absolute dose, **b** categorization based on final dose in mg/kg body weight

Adverse Events {#Sec10}
--------------

The side effects reported by the 34 patients while taking prazosin are shown in Table [1](#Tab1){ref-type="table"}. Of note, although one-quarter of patients noted side effects, only four (12%) discontinued prazosin due to side effects. Reported side effects included dizziness, anxiety and headaches. Blood pressure, heart rate and weight were closely monitored during prazosin treatment (Table [2](#Tab2){ref-type="table"}). With the exception of a return of nightmares and sleep problems in several children who stopped taking prazosin while still symptomatic for PTSD, no adverse events were noted with either planned or unplanned discontinuation of prazosin.

Discussion {#Sec11}
==========

To our knowledge, our study is the largest evaluation of prazosin for the treatment of nightmares and sleep disturbances in pediatric patients with PTSD. Herein, we retrospectively observed that prazosin treatment was associated with a clinically significant decrease in nightmares and sleep problems and that the medication was well tolerated. Furthermore, these data significantly extend the previously reported dose ranges utilized in pediatric patients with PTSD. However, several findings warrant additional discussion.

In all patients, prazosin was initiated at 1 mg nightly and titrated, gradually, to 2--3 mg QHS depending on clinical response over the first 2 weeks. Clinical response, as measured by the family subjective report and the sleep subscale on the UCLA PTSD RI, guided further titration. Those patients who required a higher final dose of prazosin had exhibited delayed treatment responses compared to those whose final prazosin dose was \<5 mg/night or \<0.1 mg/kg BW/night (Fig. [1](#Fig1){ref-type="fig"}). This process of incremental increase and reassessment likely accounts for the tolerability of doses higher than those reported in the literature as well as the delay in response to treatment among patients treated ≥5 mg or ≥0.1 mg/kg BW of prazosin.

The adverse events reported by the patients are consistent with the known side-effect profile of prazosin and included dizziness and nausea. Although nearly one-quarter of patients reported side effects, only four patients (12%) discontinued prazosin secondary to these side effects. Moreover, even if it were to be assumed that all patients lost to follow-up discontinued treatment as a result of side effects, this proportion would still be 25% discontinuing (10 of 40 possible patients). Of potential clinical importance, two of the four patients who discontinued treatment did so as a result of increased nighttime anxiety after taking the prazosin. Both patients reported similar experiences of having significantly decreased hypervigilance and a subsequent feeling of being unable to keep themselves safe from potential harm at night after taking low doses of prazosin (1--2 mg QHS). Both patients had severe, chronic PTSD with dissociation, histories of chronic sexual abuse and significant comorbid anxiety disorders. Neither patient felt their trauma symptoms were pathologic, but rather saw their hypervigilance as an effective means to keep themselves safe from future abuse. In both cases, the patients were successfully treated with combination therapy of trauma focused therapy and adjuvant SSRI treatment for anxiety.

Some patients who discontinued prazosin prematurely while continuing to experience PTSD symptoms reported a return of nightmares and sleep disturbances. No patients reported symptoms consistent with rebound hypertension (e.g. headache, nausea, anxiety) or noted other side effects when prazosin was discontinued. In normotensive volunteers, prazosin does not appear to lower blood pressure compared to clonidine \[[@CR44]\]. α~2~-Agonists, such as clonidine and guanfacine \[[@CR45]\], have been associated with rebound hypertension when abruptly discontinued following chronic use, likely related to suppressed sympathetic tone \[[@CR46]\]. However, this appears to be a phenomenon specific to α~2~-agonists and is not commonly observed in α~1~-antagonists such as prazosin. Our clinical experience reinforces the current observation that prazosin discontinuation was well tolerated without the need for gradual decreases in dose prior to discontinuation.

Within this sample, patients treated with prazosin appeared to be divided into two groups, low dose responders and high dose responders. Current expert consensus indicates that appropriate dosing for prazosin ranges from 1 to 4 mg orally QHS for youth. However, in our sample, 35% were treated with ≥5 mg QHS, including six patients treated with ≥10 mg. In general, we found that youth who were sensitive to the medication (including most patients with reported side effects) were receiving doses of ≤4 mg when the side effects were reported, whereas those youth who required higher doses were less likely to report any side effects when the medication was adjusted above 4 mg. The low rate of overall side effects among our 34 patients on prazosin is understandable given the time of administration (30--60 min before bedtime) as well as the general good cardiovascular health found among pediatric populations compared to adult populations.

Cognitive behavioral therapies, such as TF-CBT, are first-line treatments for traumatized children and adolescents \[[@CR3]\], yet not all children benefit from such interventions, and the impact of these therapies on trauma-specific sleep disturbances is not well established \[[@CR2]\]. Pharmacologically, adrenergic modulating agents have demonstrated efficacy in reducing or ameliorating nighttime disturbances in adults with PTSD. Specifically, prazosin has demonstrated efficacy in the reduction of nighttime-related symptoms in multiple RCTs in adults \[[@CR47]\] and in case reports in children \[[@CR8]\]. Other antiadrenergic agents commonly used in the pediatric population, such as guanfacine and clonidine, have demonstrated mixed results in the treatment of PTSD \[[@CR3]\], although it remains possible that the utility of α~2~-agonists may be more significant on pediatric PTSD that is comorbid with ADHD \[[@CR11]\]. Future research that incorporates ANS biomarkers (e.g. sAA) may improve our understanding of the underlying pathophysiology of PTSD and treatment response and possibly lead to the identification of children who would benefit from specific psychopharmacologic treatments.

While our chart review is the largest evaluation of prazosin in pediatric patients with nightmares and sleep disturbances associated with PTSD, several important limitations warrant discussion. Given the retrospective nature of this evaluation, a control group is lacking, and some children included in the review may have experienced symptomatic improvement as a result of supportive interventions administered through the trauma clinic. Furthermore, all patients received trauma focused psychotherapy, and prazosin treatment was adjunctive and followed the failure of behavioral interventions for sleep, likely excluding some patients whose nightmare symptoms would have resolved with psychotherapeutic intervention alone. Additionally, at least four patients discontinued prazosin for 2--8 weeks, with recrudescence nightmares, which abated upon reinitiating prazosin therapy. However, in the absence of a randomized, placebo-controlled trial, the efficacy of adjunctive prazosin in reducing nightmares over time cannot be conclusively established. Weight increased over time at a rate consistent with normal growth in youth; however, future controlled studies should closely monitor weight change in youth while on prazosin. Additionally, although findings regarding vital signs and reported side effects add to the known safety and tolerability of prazosin in normotensive youth with PTSD, the sample is small and it is unlikely that rare but potentially significant side effects that could result from administering a medication with cardiovascular properties to a normotensive population would have been detected. Nonetheless, the generally healthy cardiovascular systems of children and adolescents with normally functioning compensatory mechanisms likely explain the minimal blood pressure-related difficulties in long-term trials of antiadrenergic agents in youth \[[@CR48], [@CR49]\].

Conclusion {#Sec12}
==========

Prazosin may be a helpful adjunctive treatment for nightmares and sleep disturbances associated with PTSD in pediatric patients. Our data support previous findings that prazosin is well tolerated and associated with significant decreases in nightmare frequency and severity and sleep problems in youth with PTSD who are receiving evidence-based trauma focused psychotherapies. The use of prazosin, an antiadrenergic agent, may represent an intervention that specifically targets the pathophysiology of PTSD in that autonomic hyperactivity in pediatric patients with PTSD has been consistently observed in youth for nearly two decades. Importantly, the extant evidence base for antiadrenergic medications in the treatment of PTSD-associated sleep problems, including our findings, should be applied with caution in the pediatric population, particularly in light of the relatively small samples in these studies and the lack of a control group in the present study. Randomized, prospective, controlled studies of prazosin in the treatment of nightmares in children with PTSD are urgently needed.
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